Heart Seat, which is designed to support in-home health management, will help people patients receive monitoring at home without any behaviour changes, as well as provide physicians and other caregivers with trend data from the home
The Heart Seat facilitates effortless, integrated, and consistent patient monitoring at home. (Credit: Casana Care, Inc.)
Healthcare technology company Casana has secured a $30m in series B funding to boost the development and commercialisation of its first product called Heart Seat.
With the latest financing, the company’s total funding has reached to $46m.
Led by Morningside, the financing round saw participation from Matrix Partners and series A investors such as investors General Catalyst and Outsiders Fund.
Heart Seat’s first commercial offering is anticipated to be a cuffless blood pressure monitor built into the toilet seat.
Designed to support in-home health management, the new product will help people manage and control high blood pressure called hypertension.
The IoT health monitoring toilet seat will capture various measurements, including heart rate, blood pressure, and blood oxygenation.
Casana has designed the Heart Seat to help patients receive monitoring at home without any behaviour changes, as well as provide physicians and other caregivers with trend data from the home.
The latest funding will help the company to boost FDA submission of the Heart Seat and secure FDA approval to make it available to patients this year.
The company is also planning several studies to assess the potential value of the Heart Seat for health systems and risk-bearing organisations.
Casana CEO Austin McChord said, “In a world overrun with push notifications, nudges, and reminders, our product needs none of that.
“The Heart Seat is different from virtually every other vitals monitoring product, in that it takes no time out of your day and works best when you forget it’s even there.”
Casan stated that the major problem for most home health monitoring devices is poor patient compliance.
The Heart Seat is expected to help address this problem and offer improved monitoring and reporting of multiple health parameters for patients.
Casana board chairman and Vertex Pharmaceuticals chairman Dr Jeffrey Leiden said: “As healthcare moves from the doctor’s office into the home, convenient home monitoring is becoming increasingly important for patient care.
“Casana’s Heart Seat holds the unique promise of reliably and conveniently measuring multiple health parameters including Blood Pressure, Heart Rate and Oxygen Saturation, all in the privacy of the patient’s home.”